Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) Meeting Abstract
| Authors: | Chan, J.; Geyer, S.; Ou, F. S.; Knopp, M.; Behr, S.; Zemla, T.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; Trikalinos, N.; Konda, B.; Vijayvergia, N.; Dasari, N. A.; Strosberg, J.; Kohn, E. C.; Kulke, M. H.; O'Reilly, E. M.; Meyerhardt, J. A. |
| Abstract Title: | Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1292 |
| Language: | English |
| ACCESSION: | WOS:001087480203533 |
| DOI: | 10.1016/j.annonc.2023.10.047 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA53 -- Source: Wos |
